Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-α therapy

K B Bukan; A Nardo-Marino; C Hagdrup; M Boennelycke; M F Breinholdt; C Schöllkopf; H V Nielsen; D El Fassi

doi:10.1080/03009742.2018.1533035

Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-α therapy

K B Bukan, A Nardo-Marino, C Hagdrup, M Boennelycke, M F Breinholdt, C Schöllkopf, H V Nielsen, D El Fassi

2 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Scandinavian Journal of Rheumatology
Vol/bind	48
Udgave nummer	4
Sider (fra-til)	342-343
Antal sider	2
ISSN	0300-9742
DOI	https://doi.org/10.1080/03009742.2018.1533035
Status	Udgivet - 2019

Adgang til dokumentet

10.1080/03009742.2018.1533035

Andre filer og links

Link to publication in Scopus

Citationsformater

Bukan, K. B., Nardo-Marino, A., Hagdrup, C., Boennelycke, M., Breinholdt, M. F., Schöllkopf, C., Nielsen, H. V., & El Fassi, D. (2019). Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-α therapy. Scandinavian Journal of Rheumatology, 48(4), 342-343. https://doi.org/10.1080/03009742.2018.1533035

Bukan, KB, Nardo-Marino, A, Hagdrup, C, Boennelycke, M, Breinholdt, MF, Schöllkopf, C, Nielsen, HV & El Fassi, D 2019, 'Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-α therapy', Scandinavian Journal of Rheumatology, bind 48, nr. 4, s. 342-343. https://doi.org/10.1080/03009742.2018.1533035

@article{d11a4f2b851a4440bd6672ff226750ad,

title = "Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-α therapy",

keywords = "Aged, Antirheumatic Agents/administration \& dosage, Bone Marrow Examination/methods, Dexamethasone/administration \& dosage, Fatal Outcome, Humans, Immunoglobulins, Intravenous/administration \& dosage, Infliximab/administration \& dosage, Leishmaniasis, Visceral/diagnosis, Lymphohistiocytosis, Hemophagocytic/diagnosis, Male, Patient Care Management/methods, Sarcoidosis/drug therapy, Tumor Necrosis Factor-alpha/antagonists \& inhibitors",

author = "Bukan, \{K B\} and A Nardo-Marino and C Hagdrup and M Boennelycke and Breinholdt, \{M F\} and C Sch{\"o}llkopf and Nielsen, \{H V\} and \{El Fassi\}, D",

year = "2019",

doi = "10.1080/03009742.2018.1533035",

language = "English",

volume = "48",

pages = "342--343",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation

T2 - a potential adverse event to anti-tumour necrosis factor-α therapy

AU - Bukan, K B

AU - Nardo-Marino, A

AU - Hagdrup, C

AU - Boennelycke, M

AU - Breinholdt, M F

AU - Schöllkopf, C

AU - Nielsen, H V

AU - El Fassi, D

PY - 2019

Y1 - 2019

KW - Aged

KW - Antirheumatic Agents/administration & dosage

KW - Bone Marrow Examination/methods

KW - Dexamethasone/administration & dosage

KW - Fatal Outcome

KW - Humans

KW - Immunoglobulins, Intravenous/administration & dosage

KW - Infliximab/administration & dosage

KW - Leishmaniasis, Visceral/diagnosis

KW - Lymphohistiocytosis, Hemophagocytic/diagnosis

KW - Male

KW - Patient Care Management/methods

KW - Sarcoidosis/drug therapy

KW - Tumor Necrosis Factor-alpha/antagonists & inhibitors

UR - https://www.scopus.com/pages/publications/85058400197

U2 - 10.1080/03009742.2018.1533035

DO - 10.1080/03009742.2018.1533035

M3 - Letter

C2 - 30526204

SN - 0300-9742

VL - 48

SP - 342

EP - 343

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - 4

ER -